CN116333094A - 一种重组人源化I型胶原蛋白α1及表达载体和应用 - Google Patents
一种重组人源化I型胶原蛋白α1及表达载体和应用 Download PDFInfo
- Publication number
- CN116333094A CN116333094A CN202310055281.XA CN202310055281A CN116333094A CN 116333094 A CN116333094 A CN 116333094A CN 202310055281 A CN202310055281 A CN 202310055281A CN 116333094 A CN116333094 A CN 116333094A
- Authority
- CN
- China
- Prior art keywords
- collagen
- recombinant
- type
- alpha
- expression vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013604 expression vector Substances 0.000 title claims abstract description 27
- 108010029483 alpha 1 Chain Collagen Type I Proteins 0.000 title abstract description 10
- 102000008186 Collagen Human genes 0.000 claims abstract description 97
- 108010035532 Collagen Proteins 0.000 claims abstract description 97
- 229920001436 collagen Polymers 0.000 claims abstract description 97
- 230000014509 gene expression Effects 0.000 claims abstract description 31
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 30
- 230000000694 effects Effects 0.000 claims abstract description 10
- 210000003292 kidney cell Anatomy 0.000 claims abstract description 7
- 230000001737 promoting effect Effects 0.000 claims abstract description 7
- 210000001161 mammalian embryo Anatomy 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 38
- 239000000243 solution Substances 0.000 claims description 21
- 239000005090 green fluorescent protein Substances 0.000 claims description 17
- 239000013612 plasmid Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 13
- 101000875027 Homo sapiens Collagen alpha-1(X) chain Proteins 0.000 claims description 11
- 102000044123 human COL10A1 Human genes 0.000 claims description 11
- 239000002609 medium Substances 0.000 claims description 10
- 230000028327 secretion Effects 0.000 claims description 10
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 238000001976 enzyme digestion Methods 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 7
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 7
- 241000223104 Trypanosoma Species 0.000 claims description 7
- 102000019199 alpha-Mannosidase Human genes 0.000 claims description 7
- 108010012864 alpha-Mannosidase Proteins 0.000 claims description 7
- 239000006143 cell culture medium Substances 0.000 claims description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 6
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 3
- 239000001569 carbon dioxide Substances 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 3
- 239000012679 serum free medium Substances 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 238000001890 transfection Methods 0.000 claims description 3
- 239000012096 transfection reagent Substances 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 238000003151 transfection method Methods 0.000 claims description 2
- 230000019305 fibroblast migration Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 32
- 102000004169 proteins and genes Human genes 0.000 abstract description 30
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract description 12
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract description 12
- 230000012292 cell migration Effects 0.000 abstract description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract description 6
- 241000588724 Escherichia coli Species 0.000 abstract description 5
- 238000011160 research Methods 0.000 abstract description 5
- 230000004927 fusion Effects 0.000 abstract description 4
- 230000009465 prokaryotic expression Effects 0.000 abstract description 4
- 239000013613 expression plasmid Substances 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 abstract description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 17
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 12
- 241000723792 Tobacco etch virus Species 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 102000037865 fusion proteins Human genes 0.000 description 9
- 108020001507 fusion proteins Proteins 0.000 description 9
- 229910052759 nickel Inorganic materials 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 238000005520 cutting process Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000004481 post-translational protein modification Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 210000004087 cornea Anatomy 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000012880 LB liquid culture medium Substances 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 102000014870 Collagen Type XII Human genes 0.000 description 1
- 108010039001 Collagen Type XII Proteins 0.000 description 1
- 102100033601 Collagen alpha-1(I) chain Human genes 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108050002220 Green fluorescent protein, GFP Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000945357 Homo sapiens Collagen alpha-1(I) chain Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 101000933967 Pseudomonas phage KPP25 Major capsid protein Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005157 neural retina Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (9)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310055281.XA CN116333094B (zh) | 2023-02-04 | 2023-02-04 | 一种重组人源化I型胶原蛋白α1及表达载体和应用 |
PCT/CN2023/142064 WO2024159985A1 (zh) | 2023-02-04 | 2023-12-26 | 一种重组人源化I型胶原蛋白α1及表达载体和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310055281.XA CN116333094B (zh) | 2023-02-04 | 2023-02-04 | 一种重组人源化I型胶原蛋白α1及表达载体和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116333094A true CN116333094A (zh) | 2023-06-27 |
CN116333094B CN116333094B (zh) | 2024-03-29 |
Family
ID=86891946
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310055281.XA Active CN116333094B (zh) | 2023-02-04 | 2023-02-04 | 一种重组人源化I型胶原蛋白α1及表达载体和应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN116333094B (zh) |
WO (1) | WO2024159985A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116925240A (zh) * | 2023-08-09 | 2023-10-24 | 山东多美康生物医药有限公司 | 一种重组胶原蛋白及其表达方法和应用 |
WO2024159985A1 (zh) * | 2023-02-04 | 2024-08-08 | 山东多美康生物医药有限公司 | 一种重组人源化I型胶原蛋白α1及表达载体和应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020142391A1 (en) * | 1991-06-12 | 2002-10-03 | Kivirikko Kari I. | Synthesis of human procollagens and collagens in recombinant DNA systems |
CN101182355A (zh) * | 2007-10-22 | 2008-05-21 | 中国人民解放军海军医学研究所 | 抗菌肽融合蛋白基因、其重组载体、其转化体及其表达产物 |
CN101501216A (zh) * | 2006-03-06 | 2009-08-05 | 胡玛基因公司 | 制备重组人凝血酶的方法 |
CN104313053A (zh) * | 2014-10-24 | 2015-01-28 | 华南农业大学 | 一种生产人源胶原蛋白ⅱ型的方法 |
CN108884441A (zh) * | 2016-03-16 | 2018-11-23 | 洋蓟治疗有限公司 | 集落形成培养基及其用途 |
CN110964099A (zh) * | 2019-02-20 | 2020-04-07 | 江苏悦智生物医药有限公司 | 酵母重组人源I型胶原α1链蛋白、合成方法及其应用 |
WO2021212627A1 (zh) * | 2020-04-24 | 2021-10-28 | 南通大学 | 一种重组人胶原蛋白及其构建方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103725622A (zh) * | 2013-12-19 | 2014-04-16 | 西安巨子生物基因技术股份有限公司 | 一种转基因毕赤酵母基因工程菌及其构建方法与应用 |
US11180541B2 (en) * | 2017-09-28 | 2021-11-23 | Geltor, Inc. | Recombinant collagen and elastin molecules and uses thereof |
CN116333094B (zh) * | 2023-02-04 | 2024-03-29 | 山东多美康生物医药有限公司 | 一种重组人源化I型胶原蛋白α1及表达载体和应用 |
CN116218864B (zh) * | 2023-04-10 | 2024-01-09 | 山东多美康生物医药有限公司 | 一种重组Ⅲ型人源化胶原蛋白α1及其表达载体和应用 |
-
2023
- 2023-02-04 CN CN202310055281.XA patent/CN116333094B/zh active Active
- 2023-12-26 WO PCT/CN2023/142064 patent/WO2024159985A1/zh unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020142391A1 (en) * | 1991-06-12 | 2002-10-03 | Kivirikko Kari I. | Synthesis of human procollagens and collagens in recombinant DNA systems |
CN101501216A (zh) * | 2006-03-06 | 2009-08-05 | 胡玛基因公司 | 制备重组人凝血酶的方法 |
CN101182355A (zh) * | 2007-10-22 | 2008-05-21 | 中国人民解放军海军医学研究所 | 抗菌肽融合蛋白基因、其重组载体、其转化体及其表达产物 |
CN104313053A (zh) * | 2014-10-24 | 2015-01-28 | 华南农业大学 | 一种生产人源胶原蛋白ⅱ型的方法 |
CN108884441A (zh) * | 2016-03-16 | 2018-11-23 | 洋蓟治疗有限公司 | 集落形成培养基及其用途 |
CN110964099A (zh) * | 2019-02-20 | 2020-04-07 | 江苏悦智生物医药有限公司 | 酵母重组人源I型胶原α1链蛋白、合成方法及其应用 |
WO2021212627A1 (zh) * | 2020-04-24 | 2021-10-28 | 南通大学 | 一种重组人胶原蛋白及其构建方法 |
Non-Patent Citations (1)
Title |
---|
颜春洪等: "人基质金属蛋白酶-9在酵母Pichia pastoris中的表达", 中国生物化学与分子生物学报, vol. 16, no. 02, 10 April 2000 (2000-04-10), pages 194 - 199 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024159985A1 (zh) * | 2023-02-04 | 2024-08-08 | 山东多美康生物医药有限公司 | 一种重组人源化I型胶原蛋白α1及表达载体和应用 |
CN116925240A (zh) * | 2023-08-09 | 2023-10-24 | 山东多美康生物医药有限公司 | 一种重组胶原蛋白及其表达方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2024159985A1 (zh) | 2024-08-08 |
CN116333094B (zh) | 2024-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110845603B (zh) | 人胶原蛋白17型多肽、其生产方法和用途 | |
CN116333094B (zh) | 一种重组人源化I型胶原蛋白α1及表达载体和应用 | |
CN111334512B (zh) | 含羟脯氨酸与羟赖氨酸的重组类人胶原蛋白及其生产方法 | |
CN116218864B (zh) | 一种重组Ⅲ型人源化胶原蛋白α1及其表达载体和应用 | |
EP3660045A1 (en) | Polypeptide, process for the production thereof and use thereof | |
CN112552393B (zh) | 一种重组人源iii型胶原蛋白及其毕赤酵母重组表达系统 | |
WO2017206326A1 (zh) | 一种重组人源胶原蛋白及其编码基因和制备方法 | |
CN114106150B (zh) | 重组胶原蛋白、制备方法及其应用 | |
EP4349871A1 (en) | Polypeptide and use thereof | |
CN115558612A (zh) | 重组全长ⅲ型人源化胶原蛋白酵母工程菌株及构建方法 | |
BR112013010522B1 (pt) | Método para purificação de fator estimulador de colônias de granulócitos humanos a partir de e. coli recombinante | |
CN116535520A (zh) | 一种细胞外基质蛋白融合蛋白及其制备方法和应用 | |
CN118047857A (zh) | 一种生物合成人体结构性材料的制备方法 | |
CN112851791B (zh) | 一种新型抗代谢紊乱的fgf类似物及其应用 | |
CN116836263B (zh) | 一种重组人源iii型胶原蛋白及其毕赤酵母重组表达系统 | |
CN116925240A (zh) | 一种重组胶原蛋白及其表达方法和应用 | |
CN108949870B (zh) | 一种生产重组血小板源生长因子的方法 | |
CN111423516A (zh) | 一种蛋白及其在创口修复及抑菌中的应用 | |
EP3575391A1 (en) | Hydrogels for cultivating pancreatic organoids | |
CN104861076B (zh) | 一种融合多肽及其在促进成骨和血管形成中的应用 | |
WO2024187916A1 (zh) | 一种具有164.88°三螺旋结构低分子量胶原蛋白 | |
CN118324899B (zh) | 一种重组xvii型人源化胶原蛋白、制备方法及其应用 | |
CN117467024A (zh) | 融合标签重组胶原蛋白及其表达和应用 | |
CN118497019A (zh) | 提高重组人源i型胶原蛋白产量的基因工程菌及生产方法 | |
CN118638852A (zh) | 一种重组人源化iii型胶原蛋白制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240304 Address after: 218 meters north of the intersection of Qingnian Road and Dingdang Road, Tianzhong Street, Dingtao District, Heze City, Shandong Province, 274100 Applicant after: Shandong duomeikang biomedical Co.,Ltd. Country or region after: China Address before: 102299 Beijing Changping District science and Technology Park 37, 6 4 4 Applicant before: Beijing century Wei Medicine Technology Co.,Ltd. Country or region before: China |
|
GR01 | Patent grant | ||
GR01 | Patent grant |